Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | DHODH | Q02127 | 8/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6087023 | 1.00 | MAPT (0.49) | MAPTKMT2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL3905980 | 0.85 | MAPT (0.48) | MAPTKMT2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL3905983 | 0.85 | MAPT (0.48) | MAPTKMT2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL14574219 | 0.83 | MAPT (0.44) | MAPTKMT2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL6088011 | 0.82 | MAPT (0.55) | MAPTKMT2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL6088005 | 0.82 | MAPT (0.55) | MAPTKMT2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL6086376 | 0.82 | MAPT (0.45) | MAPTKMT2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL6086365 | 0.82 | MAPT (0.45) | MAPTKMT2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL6087687 | 0.80 | MAPT (0.43) | MAPTKMT2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL6087691 | 0.80 | MAPT (0.43) | MAPTKMT2AKDM4EMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060079503-A1 | Thiazolidinones and the use therof as polo-like kinase inhibitors | SCHERING AKTIENGESELLSCHAFT | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079503-A1 | Thiazolidinones and the use therof as polo-like kinase inhibitors | PLK4, PLK2, PLK3 | MAPT 1138/4885KMT2A 3723/4885KDM4E 4185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.